ReviewViruses2013
Respiratory syncytial virus: current progress in vaccine development.
Review in Viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.Virologica Sinica · 2015Pooled it
- Quality of life for parents of children with influenza-like illness: development and validation of Care-ILI-QoL.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Trial
- Comparison of the protective effect of human respiratory syncytial virus Pre-F protein combined with different adjuvants in BALB/c mice.Frontiers in immunology · 2026Article
- Vaccine Design Informed by Virus-Induced Immunity.Viral immunology · 2020Review
- Application of metabolomics in viral pneumonia treatment with traditional Chinese medicine.Chinese medicine · 2019Review
- Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.Human vaccines & immunotherapeutics · 2017Article
- CD4Vaccine · 2017Article
- Human Respiratory Syncytial Virus: Infection and Pathology.Seminars in respiratory and critical care medicine · 2016Review
- Application of Traditional Chinese Medical Herbs in Prevention and Treatment of Respiratory Syncytial Virus.Evidence-based complementary and alternative medicine : eCAM · 2016Review
- Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.Expert review of vaccines · 2016Review
- Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus.PloS one · 2016Article
- Article
- Cross-immunity between strains explains the dynamical pattern of paramyxoviruses.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.International immunology · 2015Article
- Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Current opinion in virology · 2015Review
- Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Infectious diseases and therapy · 2014Review
- Article
- Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010-2013): age distribution, seasonality and association between prevalent genotypes and disease severity.Epidemiology and infection · 2014Article
- Rapid replacement of human respiratory syncytial virus A with the ON1 genotype having 72 nucleotide duplication in G gene.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2014Article
- The impact of influenza-like illness in young children on their parents: a quality of life survey.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.